Lantheus Holdings, Inc. $LNTH Shares Bought by Intech Investment Management LLC

Intech Investment Management LLC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 28.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 81,221 shares of the medical equipment provider’s stock after acquiring an additional 17,849 shares during the quarter. Intech Investment Management LLC owned approximately 0.12% of Lantheus worth $5,405,000 at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in shares of Lantheus by 1.7% in the third quarter. Vanguard Group Inc. now owns 6,952,418 shares of the medical equipment provider’s stock worth $356,590,000 after acquiring an additional 115,338 shares during the last quarter. M&T Bank Corp acquired a new position in shares of Lantheus in the fourth quarter worth $370,950,000. TD Asset Management Inc raised its holdings in shares of Lantheus by 25.0% in the third quarter. TD Asset Management Inc now owns 790,950 shares of the medical equipment provider’s stock worth $40,568,000 after acquiring an additional 158,358 shares during the last quarter. William Blair Investment Management LLC increased its stake in Lantheus by 46.7% in the third quarter. William Blair Investment Management LLC now owns 574,681 shares of the medical equipment provider’s stock valued at $29,475,000 after purchasing an additional 183,059 shares during the last quarter. Finally, Mackenzie Financial Corp increased its stake in Lantheus by 0.6% in the third quarter. Mackenzie Financial Corp now owns 501,593 shares of the medical equipment provider’s stock valued at $25,727,000 after purchasing an additional 2,950 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LNTH has been the subject of several analyst reports. Truist Financial reiterated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research note on Monday, May 11th. B. Riley Financial reiterated a “buy” rating on shares of Lantheus in a research note on Friday, May 1st. Jefferies Financial Group reiterated a “buy” rating and issued a $110.00 target price on shares of Lantheus in a research note on Tuesday, March 17th. William Blair reiterated an “outperform” rating on shares of Lantheus in a research note on Tuesday, March 17th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research note on Tuesday, May 26th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $101.86.

Lantheus Stock Performance

Lantheus stock opened at $99.30 on Monday. The firm has a market capitalization of $6.47 billion, a P/E ratio of 23.93 and a beta of -0.03. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. The stock has a fifty day moving average price of $85.66 and a 200 day moving average price of $73.49. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $103.89.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 EPS for the quarter, topping the consensus estimate of $1.25 by $0.21. The company had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The firm’s revenue was up 1.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.53 earnings per share. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 4.41 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.